Efor news
30/04/2026
Major Evolutions of EU GMP Chapters 1 and 4: Towards a Reinforced Governance of Quality, Data, and Knowledge
European regulatory authorities have initiated a revision of Chapter 1 (Pharmaceutical Quality System) and Chapter 4 (Documentatio
23/04/2026
SynDIAG: Lyon-Based Consortium, Including Efor’s Data Science Teams, Launches Next-Generation Respiratory Infection Diagnostic Platform
A new consortium led by AXO Science and involving Efor Data Science teams has officially launched SynDIAG
16/04/2026
Design Transfer according to ISO 13485:2016: From Development to Medical-Device Production
Design and development, which culminate in design transfer, are pivotal stages in the life cycle of a medical device.
9/04/2026
Efor strengthens its presence in Asia with the opening of a new office in Shanghai
Efor continues its international expansion with the inauguration of its new Shanghai offices.
2/04/2026
Nitrosamine Impurities in Pharmaceuticals: Chemistry, Evolving Regulations and Strategic Risk Control
Nitrosamines are highly reactive, potentially DNA-damaging chemicals
Join our team
Consult our offers
26/03/2026
Efor strengthens its U.S. presence with a new office in Houston
Efor is continuing its expansion in North America with the opening of a new office in Houston, Texas.
19/03/2026
Reimbursement of Health Products in France: A Public-Health and Market-Access Issue
This article provides a concise overview of the reimbursement dossier journey, outlining its stakes, the key stakeholders involved
12/03/2026
International Women’s Day: Celebrating the women who shape Efor
On the occasion of International Women’s Day, Efor celebrates the women who contribute every day to our collective success.
5/03/2026
No Deviation joins Efor, strengthening our presence in Asia
Efor welcomes No Deviation, a Singapore based company recognized for its expertise in CQV, CSV, Quality Compliance, and Digit
5/03/2026
The Talc Debate: Health Risks and Controversies
A seemingly harmless natural mineral, talc has once again become the focus of a major public-health debate in 2025
4/03/2026
DynamixE joins Efor, strengthening our execution platform in North America
This is not a “day one” relationship. Efor and DynamixE teams are already collaborating on several large US projects, with ali
26/02/2026
Efor successfully completes a €300m refinancing to support its international growth strategy
Efor announces the refinancing of its existing debt for an amount of approximately €300 million.
